Talecris Biotherapeutics has completed the largest biopharmaceutical IPO for three years, raising $550 million for its own operations through a total $950 million offering.
Nearly 29 million shares were offered by Talecris itself, while 21 million were offered by the selling stockholder Talecris Holdings and the limited partnerships affiliated with Ampersand Ventures, which...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?